Rivaroxaban antithrombotics
systematic review meta-analysis network meta-analysis
 

BAY 59-7939 - Xarelto      

Select             pdf
Filter

  • Group by...
Trial Studied trt Control trt patientstagsROB Trial resultAll cause deathMajor bleeding

acute coronary syndrome  

ATLAS ACS 2 - TIMI 51 (2.5mg), 2011      NCTrivaroxaban 2.5mgplaceboLow risk of bias suggesting -33%243%
ATLAS ACS-TIMI 46 (2.5mg), 2009      NCTrivaroxaban 2.5mgplaceboLow risk of bias negative276%
ATLAS ACS 2 - TIMI 51 (5mg), 2011      NCTrivaroxaban 5mgplacebosuggesting -58%333%
ATLAS ACS-TIMI 46 (5mg), 2009      NCTrivaroxaban 5mgplaceboLow risk of bias negative 1664%

atrial fibrillation  

ROCKET (2nd prevention subgroup) , 2011   rivaroxabanwarfarinLow risk of bias negative
ROCKET-AF, 2010        NCTrivaroxabanwarfarin standard doseLow risk of bias suggesting -8%4%

cardiovascular prevention  

COMPASS (rivaroxaban alone), 2017    NCTrivaroxabanaspirinsecondary prevention -
COMPASS (rivaroxaban + aspirin), 2017      NCTrivaroxaban + aspirinaspirinsecondary preventionLow risk of bias - 8100%

heart failure  

COMMANDER HF, 2018      NCTrivaroxabanplacebonegative-2%

post stroke  

NAVIGATE ESUS, 2018      NCTrivaroxabanaspirin -

pulmonary embolism  

Einstein-PE Evaluation, 2012      NCTrivaroxaban (without LMWH)LMWH/VKARisk of bias -

thrombosis prevention  

MARINER, 2018        NCTrivaroxabanplacebomedical patientsLow risk of bias suggesting -20%88%
RECORD 1, 2008      NCTrivaroxabanenoxaparinhip surgeryLow risk of bias suggesting-2%202%
RECORD 3, 2008    NCTrivaroxabanenoxaparin (europe regimen)knee surgeryLow risk of bias suggesting-100%19%
ODIXa-HIP 10mg, 2006   rivaroxabanenoxaparin (short duration)hip surgeryLow risk of bias suggesting
RECORD 2, 2008    NCTrivaroxaban (long duration)enoxaparin (short duration)hip surgeryLow risk of bias suggesting-66%0%
ODIXa-KNEE, 2005   rivaroxabanenoxaparin (US regimen)knee surgeryLow risk of bias negative-100%
RECORD 4, 2009    NCTrivaroxabanenoxaparin (US regimen)knee surgeryLow risk of bias suggesting-34%147%

venous thrombosis  

SELECT D, 2018     rivaroxabandalteparinpatients with cancerRisk of bias suggesting 83%
EINSTEIN-extension, 2009    NCTrivaroxabandiscontinuationLow risk of bias suggesting -51%∞%
EINSTEIN (subgroup), 2014     rivaroxabanenoxaparinpatients with cancersuggesting-7%-58%
Einstein-DVT Dose-Ranging Study, 2008     rivaroxaban (without LMWH)LMWH/VKA -
Einstein-DVT Evaluation, 2010    NCTrivaroxaban (without LMWH)LMWH/VKA DOAC without heparin Low risk of bias suggesting-23%-30%
Einstein-PE Evaluation, 2012      NCTrivaroxaban (without LMWH)LMWH/VKARisk of bias -



- About - Browse pathology | treatment - Site map - Credits Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons